vs
BGC Group, Inc.（BGC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
BGC Group, Inc.的季度营收约是Royalty Pharma plc的1.0倍（$638.6M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 2.3%，领先32.2%），BGC Group, Inc.同比增速更快（34.4% vs 4.8%），过去两年BGC Group, Inc.的营收复合增速更高（18.7% vs 4.6%）
BGC集团是一家总部位于纽约和伦敦的美国全球性金融服务企业，最初隶属于康托·菲茨杰拉德集团，2004年正式独立运营，业务范围覆盖全球金融市场相关服务领域。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
BGC vs RPRX — 直观对比
营收规模更大
BGC
是对方的1.0倍
$622.0M
营收增速更快
BGC
高出29.6%
4.8%
净利率更高
RPRX
高出32.2%
2.3%
两年增速更快
BGC
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $638.6M | $622.0M |
| 净利润 | $14.4M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | 62.4% |
| 净利率 | 2.3% | 34.4% |
| 营收同比 | 34.4% | 4.8% |
| 净利润同比 | -43.0% | 2.9% |
| 每股收益（稀释后） | $0.03 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGCRPRX
| Q4 25 | $638.6M | $622.0M | ||
| Q3 25 | $620.8M | $609.3M | ||
| Q2 25 | $648.0M | $578.7M | ||
| Q1 25 | $534.6M | $568.2M | ||
| Q4 24 | $475.2M | $593.6M | ||
| Q3 24 | $448.9M | $564.7M | ||
| Q2 24 | $435.0M | $537.3M | ||
| Q1 24 | $453.6M | $568.0M |
净利润BGCRPRX
| Q4 25 | $14.4M | $214.2M | ||
| Q3 25 | $27.9M | $288.2M | ||
| Q2 25 | $57.5M | $30.2M | ||
| Q1 25 | $55.2M | $238.3M | ||
| Q4 24 | $25.2M | $208.2M | ||
| Q3 24 | $14.7M | $544.0M | ||
| Q2 24 | $37.8M | $102.0M | ||
| Q1 24 | $49.2M | $4.8M |
营业利润率BGCRPRX
| Q4 25 | 3.9% | 62.4% | ||
| Q3 25 | 5.4% | 70.1% | ||
| Q2 25 | 11.6% | 36.3% | ||
| Q1 25 | 15.0% | 94.0% | ||
| Q4 24 | 5.7% | 60.9% | ||
| Q3 24 | 4.4% | — | ||
| Q2 24 | 12.7% | 50.2% | ||
| Q1 24 | 15.7% | -13.0% |
净利率BGCRPRX
| Q4 25 | 2.3% | 34.4% | ||
| Q3 25 | 4.5% | 47.3% | ||
| Q2 25 | 8.9% | 5.2% | ||
| Q1 25 | 10.3% | 41.9% | ||
| Q4 24 | 5.3% | 35.1% | ||
| Q3 24 | 3.3% | 96.3% | ||
| Q2 24 | 8.7% | 19.0% | ||
| Q1 24 | 10.8% | 0.8% |
每股收益（稀释后）BGCRPRX
| Q4 25 | $0.03 | $0.49 | ||
| Q3 25 | $0.06 | $0.67 | ||
| Q2 25 | $0.11 | $0.07 | ||
| Q1 25 | $0.11 | $0.55 | ||
| Q4 24 | $0.04 | $0.46 | ||
| Q3 24 | $0.03 | $1.21 | ||
| Q2 24 | $0.08 | $0.23 | ||
| Q1 24 | $0.10 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $851.5M | $618.7M |
| 总债务越低越好 | $1.5B | $9.0B |
| 股东权益账面价值 | $972.5M | $9.7B |
| 总资产 | $4.4B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.58× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资BGCRPRX
| Q4 25 | $851.5M | $618.7M | ||
| Q3 25 | $774.9M | $938.9M | ||
| Q2 25 | $827.8M | $631.9M | ||
| Q1 25 | $966.4M | $1.1B | ||
| Q4 24 | $711.6M | $929.0M | ||
| Q3 24 | $563.5M | $950.1M | ||
| Q2 24 | $571.7M | $1.8B | ||
| Q1 24 | $566.8M | $843.0M |
总债务BGCRPRX
| Q4 25 | $1.5B | $9.0B | ||
| Q3 25 | $1.8B | $8.9B | ||
| Q2 25 | $1.8B | $8.0B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.6B | ||
| Q3 24 | $1.4B | $7.6B | ||
| Q2 24 | $1.4B | $7.6B | ||
| Q1 24 | $945.0M | $6.1B |
股东权益BGCRPRX
| Q4 25 | $972.5M | $9.7B | ||
| Q3 25 | $965.3M | $9.6B | ||
| Q2 25 | $930.5M | $9.5B | ||
| Q1 25 | $963.8M | $9.8B | ||
| Q4 24 | $898.5M | $10.3B | ||
| Q3 24 | $860.1M | $10.3B | ||
| Q2 24 | $858.1M | $9.8B | ||
| Q1 24 | $912.1M | $9.9B |
总资产BGCRPRX
| Q4 25 | $4.4B | $19.6B | ||
| Q3 25 | $5.8B | $19.3B | ||
| Q2 25 | $4.9B | $18.3B | ||
| Q1 25 | $4.9B | $17.6B | ||
| Q4 24 | $3.6B | $18.2B | ||
| Q3 24 | $4.4B | $18.0B | ||
| Q2 24 | $4.3B | $17.7B | ||
| Q1 24 | $4.4B | $16.1B |
负债/权益比BGCRPRX
| Q4 25 | 1.58× | 0.92× | ||
| Q3 25 | 1.90× | 0.93× | ||
| Q2 25 | 1.97× | 0.84× | ||
| Q1 25 | 1.19× | 0.78× | ||
| Q4 24 | 1.27× | 0.74× | ||
| Q3 24 | 1.68× | 0.74× | ||
| Q2 24 | 1.68× | 0.78× | ||
| Q1 24 | 1.04× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $180.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $175.1M | — |
| 自由现金流率自由现金流/营收 | 27.4% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 12.55× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $372.9M | — |
8季度趋势，按日历期对齐
经营现金流BGCRPRX
| Q4 25 | $180.4M | $827.1M | ||
| Q3 25 | $141.9M | $702.6M | ||
| Q2 25 | $71.2M | $364.0M | ||
| Q1 25 | $839.0K | $596.1M | ||
| Q4 24 | $251.9M | $742.5M | ||
| Q3 24 | $88.3M | $703.6M | ||
| Q2 24 | $-53.0M | $658.2M | ||
| Q1 24 | $28.1M | $664.6M |
自由现金流BGCRPRX
| Q4 25 | $175.1M | — | ||
| Q3 25 | $137.2M | — | ||
| Q2 25 | $65.0M | — | ||
| Q1 25 | $-4.4M | — | ||
| Q4 24 | $245.6M | — | ||
| Q3 24 | $78.8M | — | ||
| Q2 24 | $-63.5M | — | ||
| Q1 24 | $24.9M | — |
自由现金流率BGCRPRX
| Q4 25 | 27.4% | — | ||
| Q3 25 | 22.1% | — | ||
| Q2 25 | 10.0% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 51.7% | — | ||
| Q3 24 | 17.5% | — | ||
| Q2 24 | -14.6% | — | ||
| Q1 24 | 5.5% | — |
资本支出强度BGCRPRX
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 0.7% | — |
现金转化率BGCRPRX
| Q4 25 | 12.55× | 3.86× | ||
| Q3 25 | 5.09× | 2.44× | ||
| Q2 25 | 1.24× | 12.06× | ||
| Q1 25 | 0.02× | 2.50× | ||
| Q4 24 | 9.99× | 3.57× | ||
| Q3 24 | 5.99× | 1.29× | ||
| Q2 24 | -1.40× | 6.45× | ||
| Q1 24 | 0.57× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGC
| Commissions | $590.2M | 92% |
| Data Software And Post Trade | $36.7M | 6% |
| Fees From Related Parties | $4.6M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
